Evidence map›Paper›PMID 41355015›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2025

Regional cortical network atrophy predicts progression to dementia in the Lewy body diseases.

Rong Ye, Thiago Paranhos Pereira, Joseph J Locascio, Anna E Goodheart, Erin C Peterec, Michael Brickhouse, Bradford C Dickerson, Alexandra Touroutoglou, Stephen N Gomperts

Abstract read
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Regional cortical network atrophy predicts progression to dementia in the Lewy body diseases.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Rong YeDepartment of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA.
Thiago Paranhos PereiraDepartment of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA.
Joseph J LocascioDepartment of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA.
Anna E GoodheartDepartment of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA.
Erin C PeterecDepartment of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA.
Michael BrickhouseDepartment of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA.
Bradford C DickersonDepartment of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA.
Alexandra TouroutoglouDepartment of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA.
Stephen N GompertsDepartment of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA.

Funding

NATIONAL ALZHEIMERS COORDINATING CENTER (NACC)U01AG016976 · NIA · UNIVERSITY OF WASHINGTON · PI KUKULL, WALTER ANTHONY · 1999 to 2020
$72.8M
Harvard Clinical and Translational Science CenterUM1TR004408 · NCATS · HARVARD MEDICAL SCHOOL · PI Lindsey Robert Baden, Lee Marshall Nadler · 2023 to 2026
$43.3M
Research Education ComponentP30AG062421 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI Christine S Ritchie · 2019 to 2026
$36.5M
Grit against cognitive decline in aging and preclinical Alzheimer DiseaseR01AG085377 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI Alexandra Touroutoglou · 2024 to 2026
$2.4M
Imaging Epigenetic Mechanisms in Parkinson's Disease with [11C]MartinostatR21NS109833 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI GOMPERTS, STEPHEN N., WANG, CHANGNING · 2018 to 2019
$463k
Neuromodulation of brain network function in preclinical and prodromal Alzheimer's DiseaseR21AG080588 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI DICKERSON, BRADFORD C, TOUROUTOGLOU, ALEXANDRA · 2023 to 2024
$462k
Michael J. Fox Foundation for Parkinson's ResearchNational Institute of Neurological Disorders and Stroke (NINDS) 1R21 NS109833National Institute of Neurological Disorders and Stroke (NINDS) NIH P30AG062421National Institute of Neurological Disorders and Stroke (NINDS) U01 AG016976-11NCATS NIH HHS UM1 TR004408NIA NIH HHS P30 AG062421NIA NIH HHS R01 AG085377NIA NIH HHS R21 AG080588NIA NIH HHS U01 AG016976NINDS NIH HHS 1R21 NS109833NINDS NIH HHS R21 NS109833U.S. Department of Defense CDMRP/W81XW1810516
6 · The paper itself

Abstract

introductionThe timeline from symptom onset to the loss of independent functioning varies across patients with Lewy body disease (LBD). Here, we investigate whether the magnitude of cortical atrophy within functional networks that subserve cognitive and affective functions has utility in predicting progression to dementia in LBD.

methodsForty-six LBD patients with intact instrumental and basic activities of daily living at baseline underwent brain magnetic resonance imaging scans and longitudinal clinical assessments. Cortical atrophy was estimated in LBD patients relative to an amyloid-negative control group.

resultsMultivariate Cox regression analysis demonstrated that atrophy in the affective salience and limbic networks, but not in cognitive, motor, or visual networks, predicted progression to dementia after controlling for disease duration, diagnosis, amyloid beta status, and baseline cognitive severity. DISCUSSION: Baseline atrophy in the salience and limbic networks is an important predictor of progression to dementia and may have value in identifying early-stage LBD patients at risk for faster progression. HIGHLIGHTS: In this longitudinal study of the Massachusetts Alzheimer's Disease Research Center's Memory and Aging Cohort, although the magnitude of cortical atrophy in the early stages of Lewy body disease (LBD) was highly variable at the individual level, atrophy in the salience-limbic network predicted progression to dementia in LBD. In the early stages of LBD, each one standard deviation increase in salience-limbic atrophy doubled the risk of dementia. These findings were robust to adjustment for disease duration, diagnosis, amyloid beta status, and baseline cognitive severity.

Indexed as

Cerebral CortexDementiaLewy Body DiseaseAgedAged, 80 and overAtrophyDisease ProgressionFemaleHumansLongitudinal StudiesMagnetic Resonance ImagingMaleNeuropsychological Testsbrain network atrophydementiaLewy body diseaselongitudinalmild cognitive impairment with Lewy bodiesParkinson's disease

Identifiers

PMID41355015
PMCPMC12682588

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.